Cagrilintide vs Liraglutide

Cagrilintide is an experimental long-acting amylin drug still in development, with no FDA approvals yet. Liraglutide, sold as Saxenda or Victoza, is an FDA-approved GLP-1 receptor agonist used to treat type 2 diabetes, obesity, and reduce cardiovascular risk. The main difference is that Liraglutide is already on the market, while Cagrilintide is still being studied. Liraglutide is injected, but the delivery method for Cagrilintide is not specified in the provided facts.

AI summary of the sources below.